Advaxis, Inc. (ADXS)
Stock Price:
$0.285 USD
-0.003 (-0.90%)
Updated November 27, 1:00 PM EST - Market closed
After-hours: $0.288 +0.003 (0.91%) Nov 27, 4:58 PM
Key Info
| Market Cap |
18.89M |
| Revenue (ttm) |
254,000 |
| Net Income (ttm) |
-30.20M |
| Shares Out |
66.23M |
| EPS (ttm) |
-0.56 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
November 27 |
| Last Price |
$0.285 |
| Previous Close |
$0.288 |
| Change ($) |
-0.003 |
| Change (%) |
-0.90% |
| Day's Open |
0.300 |
| Day's Range |
0.272 - 0.308 |
| Day's Volume |
8,573,851 |
| 52-Week Range |
0.264 - 1.480 |
More Stats
| Market Cap |
18.89M |
| Enterprise Value |
1.28M |
| Earnings Date (est) |
Dec 17, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
66.23M |
| Float |
61.55M |
| EPS (basic) |
-0.49 |
| EPS (diluted) |
-0.56 |
| FCF / Share |
-0.45 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
1.51M |
| Short Ratio |
0.50 |
| Short % of Float |
2.45% |
| Beta |
3.49 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
74.39 |
| PB Ratio |
0.81 |
| Revenue |
254,000 |
| Operating Income |
-30.34M |
| Net Income |
-30.20M |
| Free Cash Flow |
-27.75M |
| Net Cash |
17.62M |
| Net Cash / Share |
0.27 |
| Gross Margin |
8,222.05% |
| Operating Margin |
-11,942.91% |
| Profit Margin |
-11,888.60% |
| FCF Margin |
-10,923.62% |
| ROA |
-36.43% |
| ROE |
-74.81% |
| ROIC |
-243.60% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Forecasts
Analyst Ratings (1)
| Buy |
1 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Low
5.00
Current: $0.285
High
5.00
Target: 5.00
*Average 12-month price target from 1 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|
| Revenue | 20.88 | 6.06 | 12.03 | 3.99 | - | 1.00 | - | - | - | 0.51 |
| Revenue Growth | 244.45% | -49.61% | 201.16% | - | - | - | - | - | - | - |
| Gross Profit | 20.88 | 6.06 | 12.03 | 3.99 | - | 1.00 | - | - | - | 0.51 |
| Operating Income | -17.97 | -70.38 | -98.45 | -76.49 | -48.70 | -19.54 | -14.69 | -12.33 | -13.02 | -7.93 |
| Net Income | -16.61 | -66.52 | -93.44 | -73.56 | -47.03 | -16.53 | -19.99 | -12.07 | -8.12 | -10.81 |
| Shares Outstanding | 15.21 | 3.43 | 2.70 | 2.36 | 1.87 | 1.14 | 0.33 | 0.17 | 0.12 | 0.08 |
| Earnings Per Share | -1.09 | -19.36 | -34.65 | -31.20 | -25.20 | -14.55 | -61.50 | -74.85 | -75.00 | -131.24 |
| Operating Cash Flow | -36.13 | -62.13 | -76.84 | -9.14 | -24.16 | -16.08 | -8.71 | -4.57 | -8.94 | -6.42 |
| Capital Expenditures | 0.03 | -1.43 | -3.45 | -3.22 | -0.97 | -0.02 | -0.02 | -0.09 | - | -0.01 |
| Free Cash Flow | -36.10 | -63.55 | -80.29 | -12.37 | -25.14 | -16.11 | -8.74 | -4.66 | -8.94 | -6.44 |
| Cash & Equivalents | 32.36 | 45.12 | 70.89 | 152 | 112 | 17.61 | 20.55 | 0.00 | 1.10 | 0.11 |
| Total Debt | - | - | - | - | 0.03 | 0.06 | 0.23 | 2.82 | 6.07 | 1.44 |
| Net Cash / Debt | 32.36 | 45.12 | 70.89 | 152 | 112 | 17.54 | 20.33 | -2.82 | -4.97 | -1.33 |
| Assets | 45.26 | 62.27 | 93.64 | 169 | 120 | 23.38 | 23.59 | 3.82 | 5.36 | 2.88 |
| Liabilities | 5.73 | 38.22 | 39.38 | 49.74 | 4.01 | 2.75 | 5.58 | 9.78 | 17.92 | 17.68 |
| Book Value | 39.53 | 24.05 | 54.26 | 119 | 116 | 20.63 | 18.00 | -5.96 | -12.57 | -14.80 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Advaxis, Inc. |
| Country |
United States |
| Employees |
35 |
| CEO |
Kenneth A. Berlin |
Stock Information
| Ticker Symbol |
ADXS |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: ADXS |
Description
Advaxis, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of Listeria monocytogenes (Lm) technology based antigen delivery product in the United States. It is developing therapies for HPV-related cancers using axalimogene filolisbac (AXAL) which is phase II clinical trial for the treatment of head and neck cancer. The company is also developing ADXS-PSA for the treatment of prostate cancer; and ADXS-NEO, an individualized Lm technology antigen delivery product developed using whole-exome sequencing of a patient's tumor to identify neoantigens. In addition, it is developing ADXS-HOT for generating potent anti-cancer immunity; and ADXS-HER2, an Lm technology antigen delivery product candidate that is designed to target HER2 expressing solid tumors, including human and canine osteosarcoma. The company has collaboration and licensing agreements with OS Therapies LLC; Amgen Inc.; Especificos Stendhal SA de CV; Merck & Co., Inc.; Aratana Therapeutics Inc.; and Global BioPharma Inc. Advaxis, Inc. was founded in 2002 and is based in Princeton, New Jersey.